EFFICACY AND SAFETY OF SWITCHING FROM ADALIMUMAB TO SARILUMAB IN AN OPEN-LABEL EXTENSION OF A PHASE 3 MONOTHERAPY TRIAL IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA)

被引：0
|
作者：
Burmester, G. R. [1 ,2 ,3 ]
Fiore, S. [4 ]
Hu, C-C [4 ]
van Hoogstraten, H. [4 ]
Lee, Bong E. [5 ]
Genovese, M. C. [6 ]
机构：
[1] Charite Univ Med Berlin, Berlin, Germany
[2] Free Univ, Berlin, Germany
[3] Humboldt Univ, Berlin, Germany
[4] Sanofi Genzyme, Bridgewater, MA USA
[5] Seoul Natl Univ, Coll Med, Seoul, South Korea
[6] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
来源：
INTERNAL MEDICINE JOURNAL | 2018年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P33
引用
收藏
页码：21 / 21
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Sarilumab in Subgroups of Patients with Rheumatoid Arthritis from 2 Phase 3 Studies
    Genovese, Mark C.
    Fleischmann, Roy
    Mangan, Erin
    van Adelsberg, Janet
    Iglesias-Rodriguez, Melitza
    Dukovic, Deborah
    Fan, Chunpeng
    Huizinga, Tom W. J.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [32] Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study
    Fleischmann, Roy M.
    Saikali, Wassim
    Lakhanpal, Sharad
    Alvarez, Daniel F.
    Cox, Donna S.
    Ianos, Claudia Ana
    Zhang, Wuyan
    Cronenberger, Carol
    Wang, Karen
    LANCET RHEUMATOLOGY, 2023, 5 (09): : 532 - 541
  • [33] Long-Term Safety and Efficacy of Olokizumab in Patients with Rheumatoid Arthritis - Results of an Open-Label Extension Study
    Feist, Eugen
    Nasonov, Evgeny
    Luggen, Michael
    Fatenejad, Saeed
    Grishin, Sergey
    Samsonov, Mikhail
    Fleischmann, Roy
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 603 - 606
  • [34] Safety and efficacy of infliximab in 263 patients with active rheumatoid arthritis (RA) despite mehtotrexate therapy: A German open label trial.
    Antoni, CE
    Dechant, C
    Haentzschel, H
    Alten, R
    Soerensen, AI
    Schwebig, A
    Kalden, JR
    Manger, B
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S84 - S84
  • [35] Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis
    Keystone, Edward C.
    Genovese, Mark C.
    Schlichting, Douglas E.
    de la Torre, Inmaculada
    Beattie, Scott D.
    Rooney, Terence P.
    Taylor, Peter C.
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (01) : 14 - 21
  • [36] SARILUMAB DOSE REDUCTION TO MANAGE LABORATORY ABNORMALITIES IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS
    Genovese, M. C.
    Fay, J.
    Parrino, J.
    Garg, A.
    Van Hoogstraten, H.
    Boddy, A.
    Martincova, R.
    Graham, N.
    Simon, J.
    Burmester, G. R.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 515 - 516
  • [37] Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East
    Hammoudeh, Mohammed
    Adel, Al Awadhi
    Hasan, Eman Haji
    Akhlaghi, Maassoumeh
    Ahmadzadeh, Arman
    Abdollahi, Bahar Sadeghi
    INTERNATIONAL JOURNAL OF RHEUMATOLOGY, 2015, 2015
  • [38] Sarilumab Dose Reduction to Manage Laboratory Abnormalities in an Open-Label Extension Study in RA Patients
    Burmester, Gerd
    Garg, Anju
    van Hoogstraten, Hubert
    Graham, Neil
    Boddy, Alex
    Parrino, Janie
    Genovese, Mark C.
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [39] SARILUMAB DOSE REDUCTION TO MANAGE LABORATORY ABNORMALITIES IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS
    Burmester, Gerd R.
    Garg, Anju
    Van Hoogstraten, Hubert
    Graham, Neil
    Boddy, Alexander
    Parrino, Janie
    Genovese, Mark C.
    INTERNAL MEDICINE JOURNAL, 2016, 46 : 40 - 41
  • [40] EFFICACY AND SAFETY OF SARILUMAB IN SUBGROUPS OF PATIENTS WITH RHEUMATOID ARTHRITIS FROM 2 PHASE-3 STUDIES
    Genovese, M. C.
    Fleischmann, R.
    Mangan, E. K.
    Iglesias-Rodriguez, M.
    Huizinga, T. W. J.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S68 - S69
12345